

1 ***Plasmodium falciparum pfhrp2 and pfhrp3* gene deletions among patients enrolled at 100**
2 **health facilities throughout Tanzania: February to July 2021**

3
4 Eric Rogier¹, Nastassia Battle², Catherine Bakari³, Misago D. Seth³, Douglas Nace¹, Camelia
5 Herman¹, Rashid A. Madebe³, Celine I. Mandara³, Beatus M. Lyimo^{3,4}, David J. Giesbrecht⁵,
6 Zachary R. Popkin-Hall⁶, Filbert Francis⁷, Daniel Mbwambo⁸, Issa Garimo⁸, Sijenunu Aaron⁸,
7 Abdallah Lusasi⁸, Fabrizio Molteni⁹, Ritha Njau¹⁰, Jane A. Cunningham¹¹, Samwel Lazaro⁸, Ally
8 Mohamed⁸, Jonathan J. Juliano⁶, Jeffrey A. Bailey⁵, Venkatachalam Udhayakumar¹, Deus S.
9 Ishengoma^{3,12,13}

10

11 ¹Malaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.

12 ²CDC Foundation, Atlanta, GA

13 ³National Institute for Medical Research, Dar es Salaam, Tanzania.

14 ⁴Nelson Mandela African Institution of Science and Technology, Arusha, Tanzania

15 ⁵Brown University, Providence, MA, USA

16 ⁶University of North Carolina, Chapel Hill, NC, USA

17 ⁷National Institute for Medical Research, Tanga, Tanzania

18 ⁸National Malaria Control Programme, Dodoma, Tanzania

19 ⁹Swiss Tropical Public Health Institute, Dar es Salaam, Tanzania

20 ¹⁰World Health Organization, Country Office, Dar es Salaam, Tanzania

21 ¹¹World Health Organization, Headquarters, Geneva, Switzerland

22 ¹²Faculty of Pharmaceutical Sciences, Monash University, Melbourne, Australia

23 ¹³Harvard T.H Chan School of Public Health, Boston, MA, USA

24

25 **Correspondence:** Eric Rogier, Centers for Disease Control and Prevention, Atlanta, GA 30029.

26 erogier@cdc.gov

27

28

29 **Abstract**

30 *Plasmodium falciparum* with the histidine rich protein 2 gene (*pfhrp2*) deleted from its genome
31 can escape diagnosis by HRP2-based rapid diagnostic tests (HRP2-RDTs). The World Health
32 Organization (WHO) recommends switching to a non-HRP2 RDT for *P. falciparum* clinical case
33 diagnosis when *pfhrp2* deletion prevalence causes $\geq 5\%$ of RDTs to return false negative
34 results. Tanzania is a country of heterogenous *P. falciparum* transmission, with some regions
35 approaching elimination and others at varying levels of control. In concordance with the current
36 recommended WHO *pfhrp2* deletion surveillance strategy, 100 health facilities encompassing
37 10 regions of Tanzania enrolled malaria-suspected patients between February and July 2021.
38 Of 7,863 persons of all ages enrolled and providing RDT result and blood sample, 3,777
39 (48.0%) were positive by the national RDT testing for *Plasmodium* lactate dehydrogenase
40 (pLDH) and/or HRP2. A second RDT testing specifically for the *P. falciparum* LDH (Pf-pLDH)
41 antigen found 95 persons (2.5% of all RDT positives) were positive, though negative by the
42 national RDT for HRP2, and were selected for *pfhrp2* and *pfhrp3* (*pfhrp2/3*) genotyping.
43 Multiplex antigen detection by laboratory bead assay found 135/7,847 (1.7%) of all blood
44 samples positive for *Plasmodium* antigens but very low or no HRP2, and these were selected
45 for genotyping as well. Of the samples selected for genotyping based on RDT or laboratory
46 multiplex result, 158 were *P. falciparum* DNA positive, and 140 had sufficient DNA to be
47 genotyped for *pfhrp2/3*. Most of these (125/140) were found to be *pfhrp2+ / pfhrp3+*, with smaller
48 numbers deleted for only *pfhrp2* (n=9) or only *pfhrp3* (n=6). No dual *pfhrp2/3* deleted parasites
49 were observed. This survey estimated that 0.24% (95% confidence interval: 0.08% to 0.39%) of
50 false-negative HRP2-RDTs for symptomatic persons were due to *pfhrp2* deletions in this 2021
51 Tanzania survey. These data provide evidence for HRP2-based diagnostics as currently
52 accurate for *P. falciparum* diagnosis in Tanzania.

53

54 **Keywords:** *Plasmodium falciparum*, Tanzania, RDT, *pfhrp2*, *pfhrp3*, gene deletion

55 Introduction

56 Scaling-up of malaria control interventions since the year 2000 has resulted in dramatic
57 decreases in *Plasmodium falciparum* cases and deaths in sub-Saharan Africa [1, 2]. However,
58 due to disruption of services in the years 2020 and 2021 due to the SARS-CoV-2 pandemic, an
59 estimated 50,000 additional malaria deaths occurred during each of those years [1], showing
60 how gains from malaria control can quickly be lost. Malaria control efforts can take many
61 different forms, including (but not limited to) insecticide treated net distribution, accurate
62 parasitological confirmation of *Plasmodium* infections, and effective case management by
63 provision of efficacious antimalarial drugs. Even these pillars of malaria control are being
64 threatened in sub-Saharan Africa through vector insecticide resistance [3, 4], *P. falciparum*
65 diagnostic resistance by *pfhrp2* gene deletions [5-7], and emergence of antimalarial drug
66 resistance genotypes [8].

67 Use of antigen-detecting rapid diagnostic tests (RDTs) has been a pragmatic strategy for
68 parasitological confirmation of *P. falciparum* infection through detection of *Plasmodium*
69 antigens, and has enabled better targeting of treatment and improved surveillance of malaria
70 [9]. The histidine-rich protein 2 (HRP2) antigen is a species-specific target for *P. falciparum*,
71 though detection of the *Plasmodium* lactate dehydrogenase (LDH) antigen can also be a
72 reliable diagnostic marker – especially for higher parasite density infections typically seen in
73 clinical cases. RDT products have been developed which have capture/detection antibodies
74 which would bind any *Plasmodium* LDH (pan-*Plasmodium*), or the *P. falciparum*- and *P. vivax*-
75 specific epitopes of this antigen [10]. Similar to the HRP2 antigen, HRP3 is expressed by *P.*
76 *falciparum* and can also supplement the detection signal for HRP2-based RDTs or other
77 immunoassays [9, 11]. Given the predominance of *P. falciparum* for the clinical relevance and
78 malaria epidemiology in sub-Saharan Africa, HRP2-based RDTs are highly preferred because
79 of thermal stability, abundance of antigen target, high species specificity, and lower cost [12].

80 Deletions of the *pfhrp2* and *pfhrp3* (*pfhrp2/3*) genes from the *P. falciparum* genome have
81 now been observed in multiple African countries and pose a serious threat to the use of these
82 antigenic markers to reliably detect *P. falciparum* infection [5-7, 9]. Natural parasite populations
83 with *pfhrp2/3* gene deletions were first reported in Peru in 2010 [13], but *P. falciparum* has since
84 been found with these gene deletions in many settings [6, 14], and has now been reported in
85 more than 35 countries [15]. The World Health Organization (WHO) has issued guidance on
86 investigating suspected false-negative RDT results due to *pfhrp2/3* gene deletions in malaria
87 parasites and is encouraging a harmonised approach to mapping and reporting the deletions
88 [16, 17]. Based on these guidelines, each country should endeavour to establish the status and
89 monitor gene deletion trends over time to see if re-assessment of national diagnostic strategy is
90 warranted when $\geq 5\%$ of *P. falciparum* clinical infections are missed by HRP2-RDTs. In
91 Tanzania, previous reports have shown sporadic occurrence of *pfhrp2* gene deletions in multiple
92 locations, though at very low levels ($< 2.0\%$) [18, 19]. However, all Tanzanian studies reported
93 to-date have utilized sampling designs different from WHO recommendations for reporting of
94 nationwide gene deletion estimates. This current study provides the first national evaluation of
95 *pfhrp2/3* gene deletions in the *P. falciparum* parasite population and provides baseline data for
96 future monitoring to establish the temporal and spatial trends of these deletions in the country.

97

98 **Methods**

99 **Ethics**

100 The study protocol was adopted from the WHO template [17] and submitted to the
101 Tanzanian Medical Research Coordinating Committee (MRCC) of the National Institute for
102 Medical Research (NIMR) for review and ethical approval. The protocol was also submitted for
103 review and approval by the ethics committee of WHO in Geneva, Switzerland. All research
104 participants were asked and provided individual consent (or assent for children aged 7-18 years
105 of age) for their participation in the survey and biobanking for future research. For children

106 under the legal age of adulthood in Tanzania (<18 years), consent was obtained from a parent
107 or guardian. An informed consent form was developed in English and translated in Kiswahili and
108 used to obtain consent both verbally and in writing from all participants. All participants agreed
109 and signed the consent or assent form or provided a thumbprint in conjunction with the
110 signature of an independent witness in case the study participant was illiterate. The project was
111 approved as a program evaluation activity and non-human subjects research by the U.S.
112 Centers for Disease Control and Prevention (CDC, project ID: 0900f3eb81f722fb).

113

114 **Study design**

115 The cross-sectional study which was undertaken as part of the ongoing project on the
116 molecular surveillance of malaria in Tanzania (MSMT)[20], conducted in collaboration with the
117 Tanzanian National Malaria Control Programme (NMCP), the President's Office, Regional
118 Administration, and Local Government authority (PO-RALG) and collaborators from USA
119 (Brown University, University of North Carolina and the CDC). Ten regions of Tanzania were
120 utilized and 100 health facilities (HF) were selected according to WHO protocol as enrolment
121 sites [21]: Dar es salaam, Dodoma, Kagera, Kilimanjaro, Manyara, Mara, Mtwara, Njombe,
122 Songwe and Tabora (Figure 1). At each HF (10 HFs from each region), patients presenting with
123 malaria-like illness were approached and to enrolled in this study after providing an informed
124 consent. Regardless of enrolment in this study, patients with malaria-like illness were provided
125 an RDT, and if positive, treated with appropriate antimalarial drugs according to Tanzania
126 national guidelines.

127

128 **Patient enrollment and sample collection procedures**

129 Inclusion criteria required patients to be aged 6 months and above, meeting case
130 definition for suspected malaria (fever in the last 48 hrs or fever at presentation with axillary
131 temperature $\geq 37.5^{\circ}\text{C}$ and/or other malaria symptoms), and requirement to reside in the same

132 area as the health facility. Exclusion criteria included previous enrollment in the study, severe
133 malaria, or other severe illnesses. For each patient, finger prick blood was collected for
134 detection of malaria infection by RDTs and also for preparation of dried blood spots (DBS) on
135 Whatman 3 MM CHR filter papers (Cytiva, USA).

136 At enrollment, each patient was tested by two types of RDTs, with the first being the
137 HRP2/pan-LDH test used by the Tanzanian NMCP for routine diagnosis of malaria (“national
138 RDT”, listed below) and the second was the *P. falciparum* LDH test donated by WHO for this
139 survey (“research RDT”), the #C14RHG25, RapiGEN Inc. BIO CREDIT Malaria Ag Pf (Pf-pLDH),
140 Republic of Korea). At the time of the survey, the Tanzanian NMCP had three types of RDTs
141 which were concurrently used in the country. They included SD Biotec Malaria Ag P.f/pan
142 (#05FK60, Standard Diagnostic Inc., India), CareStart Malaria HRP2/pLDH (#RMOM-02571,
143 AccessBio Inc., NJ, USA) and First Response Malaria Ag HRP2/pLDH Combo (#PI16FRC10s,
144 Premier Medical Corp. India). “RDT discordance” for this study was defined as a positive Pf-
145 pLDH result, but a negative HRP2 band.

146 Sample size for this survey was based on WHO master protocol [21], with a simple
147 random sampling design effect of 1.5 accounting for potential deletions of the *pfhrp2* gene. A
148 target of 37 patients with positive results by either of the two tests were enrolled from each HF
149 for a total target size of 370 samples per region and 3,700 RDT positive persons for the whole
150 study [21]. All DBS samples (positive and negative by RDTs) were stored at the HFs at ambient
151 temperature and later shipped to the NIMR Genomics Laboratory after the end of the survey for
152 storage at room temperature before shipping to the CDC in Atlanta, GA, USA for further
153 analysis.

154

155 **Sample processing and multiplex bead assay**

156 To rehydrate blood samples for *Plasmodium* antigen detection, a 6mm filter paper punch
157 from each DBS (approximately 10 μ L whole blood) was placed into 200 μ L of elution buffer:

158 phosphate buffered saline (PBS, Sigma) pH 7.2, 0.3% Tween-20, 0.5% casein (ThermoFisher),
159 0.5% bovine serum albumin (BSA, Sigma), 0.5% polyvinyl alcohol (Sigma), 0.8%
160 polyvinylpyrrolidone (Sigma), 0.02% sodium azide (Sigma), and 3 µg/mL of *E. coli* lysate (to
161 prevent nonspecific binding). This provided a 1:20 dilution of whole blood which was used as
162 the test sample for the bead-based multiplex immunoassay.

163 The bead-based multiplex assay for malaria antigen detection was performed as
164 described previously [22]. Magnetic microbeads (xMAP®, Luminex Corp., Austin, TX) were
165 covalently bound to antibodies for *Plasmodium* antigen capture by the Luminex antibody
166 coupling kit according to manufacturer's instructions. Per 12.5×10^6 beads, antibody coupling
167 concentrations were: anti-pan-*Plasmodium* aldolase antibody (pAldolase, 12.5 µg, Abcam,
168 Cambridge, UK); anti-pan-*Plasmodium* LDH (pLDH, 12.5 µg, clone M1209063, Fitzgerald,
169 Acton, MA); anti-*P. falciparum* HRP2 (20 µg, clone MPFG-55A, ICLlabs, Portland, OR); anti-*P.*
170 *falciparum* LDH (20 µg, clone M1209062, Fitzgerald). Detection antibodies were also prepared
171 in advance by biotinylating (EZ-link Micro Sulfo-NHS-Biotinylation Kit, ThermoScientific,
172 Waltham, MA) according to manufacturer's instructions. Final prepared dilution of detection
173 antibodies was 1.0 mg/mL and for anti-malarial antigen specific antibodies as follows: pAldolase
174 (Abcam), LDH (1:1 antibody mixture of M1709Pv1 and M86550, Fitzgerald), HRP2 (1:1 antibody
175 mixture of MPFG-55A and MPFM-55A, ICLlabs). All reagents were stored at 4°C until use in the
176 immunoassay.

177 For the antigen multiplex assay, reagents were diluted in buffer containing 0.1M PBS
178 (pH 7.2), 0.05% Tween-20, 0.5% BSA, and 0.02% sodium azide. Assay plates were affixed to a
179 handheld magnet (Luminex Corp) for wash steps and allowed one minute for bead
180 magnetization before evacuation of liquid and washing with 100 µL PBS/0.05% Tween-20. The
181 four bead regions were combined in dilution buffer (in a reagent trough) and pipetted onto a 96-
182 well assay plate (BioPlex Pro, BioRad, Hercules, CA) at a quantity of approximately 800
183 beads/region. Plates were washed twice, and 50 µL of controls (in duplicate) or samples (in

184 singlet) were pipetted into appropriate wells. Following 90-minute gentle shaking at room
185 temperature, protected from light, plates were washed three times. A mixture of detection
186 antibodies was prepared in dilution buffer (pAldolase at 1:2000, all others at 1:500) and 50 μ L
187 added to each well for a 45-minute incubation. After three washes, 50 μ L of streptavidin-
188 phycoerythrin (at 1:200, Invitrogen) was added for a 30-minute incubation. Plates were washed
189 three times, and 50 μ L dilution buffer was added to each well for 30-minute incubation. Plates
190 were then washed once and beads resuspended in 100 μ L PBS. After brief shaking, plates
191 were read on a MAGPIX machine (Luminex Corp) with a target of 50 beads per region. The
192 median fluorescence intensity (MFI) value was generated for all beads collected for each region
193 by assay well. Subtraction of the assay signal from wells with dilution buffer blank provided the
194 MFI-background (MFI-bg) value used for analyses. Positive and negative controls were included
195 on each assay plate to ensure valid assay results

196

197 **Selection of samples for PET-PCR Plasmodium speciation and DNA quality control**

198 Samples were initially selected for PET-PCR speciation and *pfhrp2/3* genotyping if they
199 had discordant results (point-of-care RDTs showed positivity for the Pf-pLDH band but a
200 negative HRP2 band). Based on laboratory multiplex antigen data, the second selection of
201 samples for Plasmodium speciation by PET-PCR and *pfhrp2/3* genotyping was done based on
202 the relationship between the two pan-*Plasmodium* antigens (aldolase and LDH) and the HRP2
203 and/or HRP3 (HRP2/3) signal as described previously [22], or relationship between Pf-pLDH
204 and HRP2/3. Samples were selected if completely lacking an assay signal for HRP2/3 or if the
205 assay signal for HRP2/3 was atypically lower compared to the level of pAldolase, pLDH, or Pf-
206 pLDH antigens.

207

208 **DNA extraction and quantification from samples**

209 For samples selected for genotyping, total genomic DNA was extracted from DBS
210 samples (three 6mm punches per sample) using Tween-Chelex 100 (Bio-Rad Laboratories,
211 USA) extraction method as previously described with some modifications [23]. Briefly, the
212 punched DBS samples were incubated in 1 mL of 0.5% Tween-20 (Sigma) in PBS (Thermo
213 Fisher Scientific) overnight at room temperature, placed onto the shaker at low speed to release
214 parasite DNA from red blood cells, and briefly centrifuged. Tween-PBS was removed followed
215 by washing with 1 mL of 1X PBS and incubation at 40°C for 30 min. The samples were briefly
216 centrifuged, PBS removed, and 150 µL of 10% Chelex 100 resin (BioRad) in water were added
217 to each sample and incubated for 10 min at 95°C. Supernatant was removed from the tubes
218 followed by addition of 1 mL PBS, briefly vortexed, and incubated at 4°C for 15-30 min. After a
219 brief centrifugation to precipitate the DNA from other impurities, a 2:1 solution of Chelex to
220 sterile water was added and incubated at 95°C for 10 min. Samples were centrifuged for 5 min
221 at high speed to pellet Chelex and filter paper and resulting DNA supernatants (approximately
222 150 µL) were transferred to new tubes. Supernatants were centrifuged for 10 min at 14,000 rpm,
223 and the Chelex-free supernatant (approximately 50 µL) was transferred to a new tube for
224 storage at 20°C until use in PCR assays.

225

226 **PET-PCR and genotyping for *P. falciparum* *pfhrp2* and *pfhrp3* genes**

227 PET-PCR was performed on extracted DNA as described previously to ensure quality
228 and presence of *P. falciparum* DNA [22]. Genotyping for *pfmsp1*, *pfmsp2*, and *pfhrp3* was
229 performed by nested PCR (nPCR) as described previously [22]. For *pfhrp2* genotyping,
230 conventional PCR was performed as described previously [24]. Results for *pfhrp2/3* genotyping
231 were only reported if both *pfmsp1* and *pfmsp2* (both single-copy genes in the *P. falciparum*
232 genome) were successfully amplified for a DNA sample in at least two out of three independent
233 PCR reactions [16].

234

235 Results

236 From February to July 2021, a total of 8,040 persons were enrolled among the 100
237 Tanzanian HFs (Figure 1) with a recorded RDT result and 7,863 persons (97.8%) providing
238 DBS for later laboratory assays. Of this set of DBS, 7,847 (99.8%) were able to be inventoried
239 and had laboratory multiplex antigen data collected. For all enrolled participants, median age
240 was 15 (interquartile range: 3 to 29 years), and 55.3% were female (Table 1). Numbers of
241 participants enrolled among regions were similar except Kilimanjaro which enrolled 31.6% of all
242 patients; this was due to the very low transmission setting in Kilimanjaro region and need to
243 enroll more persons to obtain the target of 37 RDT positive persons per health facility [21]. RDT
244 results found 48.2% (n=3,787) of all patients positive by any RDT utilized in the survey. For the
245 3,787 patients who showed a positive RDT result to any antigen target, 3,185 (84.1%) were
246 positive to both targets on the national RDT and 545 (14.4%) were positive only for the HRP2
247 band. The research RDT, testing only for Pf-pLDH, showed strong concordance with national
248 RDT results and 3,020 (79.7%) of persons positive by the research RDT also showed positivity
249 by the national RDT. Of these 767 testing positive only by the national RDT, and not the
250 research RDT, the majority of these (n=609, 79.4%) were only HRP2 positive, indicating a
251 lower-density *P. falciparum* infection [25]. A total of 95 persons tested positive only by the
252 research RDT, representing discordance of 2.5% of the “any RDT” positives.

253 The DBS from these 95 persons testing positive by only Pf-pLDH were selected for
254 further PCR assays based on suspicion of *P. falciparum* infection with potential deletions in the
255 *pfhrp2* (and *pfhrp3*) genes. Of these 95, nine DBS (9.5%) were unable to be retrieved, and an
256 additional 46 (48.4%) were negative for *P. falciparum* DNA, leaving 40 (42.1%) appropriate for
257 further *pfhrp2/3* genotyping. Additionally, DBS were also selected for further PCRs based on
258 results from the laboratory multiplex antigen detection assay. In comparing the laboratory-
259 detected antigen levels of HRP2/3 versus other *Plasmodium* markers (assay signal for
260 pAldolase, pLDH, and Pf-pLDH), if a blood sample was positive for any *Plasmodium* antigen,

261 the vast majority of these were observed to have high levels of HRP2/3 relative to the other
262 three targets (Figure 2). From the lab multiplex antigen assay, a total of 135 specimens (1.7%
263 of the 7,847 DBS available; shown by red shading in Figure 2) were selected for DNA extraction
264 and further assays to determine *pfhrp2/3* status of the infecting parasites. Of these 135, 118
265 (87.4%) were confirmed to have *P. falciparum* DNA to attempt the *pfhrp2/3* genotyping PCRs
266 (Figure 3). Concordance of lab antigen positivity between the blood samples from the 95
267 persons testing RDT positive only for Pf-pLDH is shown in Supplemental Figure 1.
268 Approximately half (50/95, 52.6%) of the blood samples from these “RDT discordant” persons
269 positive for any *Plasmodium* antigen by the lab multiplex assay, and only 35.8% of these blood
270 samples were positive by both the Pf-pLDH RDT and the Pf-pLDH lab assay.

271 Between the RDT discordant (n=40) and lab antigen assay (n=118) selection strategies,
272 a total of 137 *P. falciparum* infections were selected to move forward with *pfhrp2/3* genotyping
273 (Figure 3). Most of these *P. falciparum* DNA positive samples (88.6%, 140/158) were also able
274 to amplify the single-copy genes (*pfmsp1* and *pfmsp2* in this study) required for quality
275 assurance reporting of *pfhrp2/3* genotyping results. Of these 140, the majority (89.2%, 125/140)
276 were able to amplify both the *pfhrp2* and *pfhrp3* genes (a *pfhrp2+/pfhrp3+* genotype), six (4.3%)
277 showed a genotype of *pfhrp2+/pfhrp3-*, nine (6.4%) a *pfhrp2-/pfhrp3+* genotype, and no
278 parasites from *P. falciparum* infections were found to have the double-deletion *pfhrp2-/pfhrp3-*
279 genotype. All nine persons infected with *P. falciparum* with *pfhrp2* deletions were negative on
280 the national RDT for the HRP2 band.

281 *P. falciparum* infections with single gene deletions for *pfhrp2* or *pfhrp3* were found to be
282 largely dispersed throughout the country, though some clustering was observed in the southern
283 part of Njombe region (Figure 4). Due to the sampling design and rare finding of any deletions,
284 spatial inference was not attempted to denote statistically significant clustering patterns. The
285 nine infections containing *pfhrp2*-deleted *P. falciparum* were from: Dodoma (n=1), Kilimanjaro
286 (n=1), Manyara (n=2) regions in northeast Tanzania, the Njombe region in the south (n=4), and

287 Kagera region in the extreme northwest (n=1). The four *pfhrp2* deletions in Njombe were
288 enrolled at two health facilities with two infections with deleted parasites found in each. From
289 estimates reported in the year 2020 for *P. falciparum* transmission strata by region in Tanzania
290 [26], the majority of the *pfhrp2* deletions (8/9, 88.9%) were found in either “low” or “very low”
291 transmission strata (Supplemental Figure 2). The *pfhrp3*-deleted parasites were found in: Dar es
292 Salam region (n=1), Kagera region (n=2, infections from the same health facility), Njombe
293 region (n=2, infections from different health facilities), and Mbeya region (n=1). The only regions
294 to show parasites both having *pfhrp2* or *pfhrp3* deletions were Kagera and Njombe, and the
295 ones in Njombe were all noted in the far southern area of this region.

296

297 **Discussion**

298 Increasing global reports of deletions of the *pfhrp2* (and to lesser extent *pfhrp3*) genes
299 have concerned malaria stakeholders in countries heavily relying on HRP2-based RDTs for
300 clinical diagnosis of *P. falciparum* infection [15, 22]. Enrolling of 7,863 malaria suspected
301 patients in 100 health facilities throughout Tanzania in 2021 who provided a DBS sample found
302 48.2% of persons with a positive RDT result with very few individuals (n=95, 2.5% of all RDT
303 positives) testing positive for the *P. falciparum* antigen Pf-pLDH, but negative for HRP2.
304 Importantly, as all persons enrolled in this study were presenting with malaria-like symptoms,
305 from this RDT data alone it could be surmised that *P. falciparum* is the predominant species
306 causing clinical malaria in Tanzania. The concordance in test results between the two
307 independent RDTs shows a low risk of infections with *P. falciparum* not producing high levels of
308 the HRP2/3 antigen(s) – as the phenotypic indicator of deleted or non-functional *pfhrp2* (or
309 *pfhrp3*) genes [9, 13]. In assessing potential *pfhrp2/3* deletions in Tanzania for this survey,
310 multiplex antigen screening including targets for HRP2 and other *Plasmodium* antigens allowed
311 a secondary approach to also compare with RDT results and elucidate *pfhrp2/3* deletions [18,
312 27]. Of 7,847 DBS assayed by the lab multiplex assay, only 1.7% (n=135) were selected for

313 further molecular assays based on the absence, or very low levels, of HRP2 antigen in the
314 blood sample relative to the other *Plasmodium* targets. The combination of these two
315 approaches (RDT concordance and lab multiplex antigen assay) both pointed to the same
316 phenotypic findings: the vast majority of clinical malaria in Tanzania is being caused by *P.*
317 *falciparum* producing sufficient HRP2/3 antigen to elicit positive HRP2-based RDT results. The
318 inclusion of *pfhrp2/3* genotyping data for these malaria patients enrolled throughout Tanzania
319 provides further evidence for the very low prevalence of *P. falciparum* parasites causing
320 symptomatic disease that would be missed by routine HRP2-based RDTs currently utilized in
321 Tanzania. When combining the antigen and genotyping data, it is estimated here that 0.24%
322 (95% CI: 0.08-0.39%) of false-negative HRP2-RDTs were due to *pfhrp2* deletions from this
323 survey.

324 Current recommendations provided by the WHO set a threshold of 5% or greater of
325 clinical *P. falciparum* infections evading HRP2 diagnostics as criteria to re-assess use of HRP2
326 as a standard diagnostic tool in a setting [17, 21]. For numerous practical reasons, malaria
327 diagnostic strategies are typically made at the national level, so national surveys would need to
328 be inclusive of *P. falciparum* endemic settings throughout a country to most appropriately
329 generate this quantitative estimate and compare to the 5% threshold. This survey design is
330 robust and provides opportunities not only for evaluation of *pfhrp2/3* deletion status in a country,
331 but also assessment of *P. falciparum* parasite diversity (including drug resistance and
332 population genetic markers), estimation of non-falciparum clinical burden, and other malaria
333 clinical comparisons and analyses [6, 28, 29]. From this 2021 Tanzania survey, reports outlining
334 findings for putative drug resistance markers and findings of non-falciparum malaria infections
335 are forthcoming.

336 Throughout the 100 health facilities where persons were enrolled in this survey, only
337 twelve facilities enrolled persons with *P. falciparum* parasites showing any deletions: seven sites
338 with infecting parasites lacking *pfhrp2*, and five sites with infecting parasites lacking *pfhrp3*.

339 Furthermore, these twelve sites were broadly spread out throughout the country and inclusive of
340 different sub-populations of *P. falciparum* strains [30]. The notable exception to this generalized
341 finding was the observation of four health facilities in southern Njombe region enrolling persons
342 with *P. falciparum* infections with *pfhrp2* or *pfhrp3* gene deletions. However, even within this
343 “cluster”, of 180 persons enrolled among these three sites, 63% (n=113) were found to have *P.*
344 *falciparum* infections, meaning that only 3.5% (4/113) of identified *P. falciparum* infections
345 among these three sites showed *pfhrp2* single deletions. Importantly, deletions in the *pfhrp3*
346 gene are not regarded for the WHO 5% *pfhrp2* deletion threshold as this gene product (HRP3)
347 is a truncated form of the HRP2 antigen and is not thought to contribute significantly to the RDT
348 test band intensity when both antigens are present [31]. To this point, all nine *P. falciparum*
349 infections identified in this current Tanzania study which had parasites deleted for *pfhrp2* had
350 produced a negative band result for HRP2 by RDT. Future studies may look to over-sample
351 from this area of the country to see if prevalence and diagnostic impact of *pfhrp2/3* gene
352 deletions is truly higher here versus other regions. The results from this current study are
353 consistent with a previous 2017 Tanzania nationwide survey of border regions which enrolled
354 persons in their households. In this population of persons not actively seeking treatment, 32% of
355 persons were positive to any *Plasmodium* antigen targets, but no *pfhrp2/3* deletions were
356 observed [18]. However, these findings contrast to a 2018 health facility survey enrolling
357 persons in the Kilimanjaro and Tanga regions in the northeast part of the country which
358 estimated *pfhrp2* deletions at 1.6% of *P. falciparum* infections and *pfhrp3* deletions at 52% -
359 though no dual deletions were observed [19]. Different sampling strategies, enrolment during
360 different transmission seasons, and laboratory assays may ultimately lead to differences in
361 prevalence estimates for gene deletions, but results from this current study combined with the
362 previous two studies have consistently shown very low rates of *pfhrp2* deletions.

363 Though an overall low number of *pfhrp2* deletions were observed in this study, an
364 important finding was that nearly all of these (8/9, 88.9%) were discovered in the relatively lower

365 transmission central and southern regions of the country. This has been observed in previous
366 *pfhrp2/3* deletion studies as well, with these deletion genotypes affecting RDT results relatively
367 more when overall transmission and complexity of infections are reduced [32, 33]. As Tanzania
368 moves towards malaria elimination in the future, reducing overall transmission and the number
369 of *P. falciparum* strains in a patient at any one point in time may increase the risk for deletion
370 genotypes to affect HRP2-RDT accuracy.

371 This study was subject to limitations which may affect estimates or interpretation of
372 results. Patient enrolment from February to July is mostly inclusive of the rainy season in
373 Tanzania, so prevalence of these deletions leading to false negative HRP2-RDT results during
374 dry season months was not evaluated here [32]. Though the survey was designed to be
375 geographically-representative, persons were only enrolled from 10 of the 26 regions in mainland
376 Tanzania, meaning large areas and *P. falciparum* sub-populations have not been sampled.

377 *P. falciparum* infections from persons enrolled in 2021 were largely positive for the
378 *pfhrp2/3* genes and produced high levels of the HRP2 antigen to elicit true positive HRP2-RDT
379 results. From evidence generated here, the HRP2 antigen still appears to be a robust tool for
380 identification of *P. falciparum* infection in Tanzania. As these gene-deleted parasites may have
381 a selective advantage over their wild-type counterparts, or potentially be imported, future efforts
382 should continue to monitor for HRP2-RDT validity in the country.

383

384 **References**

- 385 1. World Health Organization. World malaria report 2021. Geneva, Switzerland, **2021**.
- 386 2. Gething PW, Casey DC, Weiss DJ, et al. Mapping Plasmodium falciparum Mortality in Africa between
387 1990 and 2015. *N Engl J Med* **2016**; 375:2435-45.
- 388 3. Keita M, Sogoba N, Kane F, et al. Multiple Resistance Mechanisms to Pyrethroids Insecticides in
389 *Anopheles gambiae sensu lato* Population From Mali, West Africa. *J Infect Dis* **2021**; 223:S81-S90.
- 390 4. Matowo NS, Martin J, Kulkarni MA, et al. An increasing role of pyrethroid-resistant *Anopheles*
391 *funestus* in malaria transmission in the Lake Zone, Tanzania. *Sci Rep* **2021**; 11:13457.
- 392 5. Berhane A, Anderson K, Mihreteab S, et al. Major Threat to Malaria Control Programs by Plasmodium
393 *falciparum* Lacking Histidine-Rich Protein 2, Eritrea. *Emerg Infect Dis* **2018**; 24:462-70.

- 394 6. Feleke SM, Reichert EN, Mohammed H, et al. Plasmodium falciparum is evolving to escape malaria
395 rapid diagnostic tests in Ethiopia. *Nat Microbiol* **2021**; 6:1289-99.
- 396 7. Iriart X, Menard S, Chauvin P, et al. Misdiagnosis of imported falciparum malaria from African areas
397 due to an increased prevalence of pfhrp2/pfhrp3 gene deletion: the Djibouti case. *Emerg Microbes*
398 *Infect* **2020**; 9:1984-7.
- 399 8. Uwimana A, Umulisa N, Venkatesan M, et al. Association of Plasmodium falciparum kelch13 R561H
400 genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre,
401 therapeutic efficacy study. *Lancet Infect Dis* **2021**; 21:1120-8.
- 402 9. Poti KE, Sullivan DJ, Dondorp AM, Woodrow CJ. HRP2: Transforming Malaria Diagnosis, but with
403 Caveats. *Trends Parasitol* **2020**; 36:112-26.
- 404 10. World Health Organization. Malaria rapid diagnostic test performance. Results of WHO product
405 testing of malaria RDTs: Round 8 (2016-2018). Geneva, Switzerland, **2018**.
- 406 11. Plucinski M, Aidoo M, Rogier E. Laboratory Detection of Malaria Antigens: a Strong Tool for Malaria
407 Research, Diagnosis, and Epidemiology. *Clin Microbiol Rev* **2021**; 34:e0025020.
- 408 12. Boyce MR, O'Meara WP. Use of malaria RDTs in various health contexts across sub-Saharan Africa: a
409 systematic review. *BMC Public Health* **2017**; 17:470.
- 410 13. Gamboa D, Ho MF, Bendezu J, et al. A large proportion of P. falciparum isolates in the Amazon region
411 of Peru lack pfhrp2 and pfhrp3: implications for malaria rapid diagnostic tests. *PLoS One* **2010**; 5:e8091.
- 412 14. Akinyi Okoth S, Abdallah JF, Ceron N, et al. Variation in Plasmodium falciparum Histidine-Rich Protein
413 2 (Pfhrp2) and Plasmodium falciparum Histidine-Rich Protein 3 (Pfhrp3) Gene Deletions in Guyana and
414 Suriname. *PLoS One* **2015**; 10:e0126805.
- 415 15. Thomson R, Parr JB, Cheng Q, Chenet S, Perkins M, Cunningham J. Prevalence of Plasmodium
416 falciparum lacking histidine-rich proteins 2 and 3: a systematic review. *Bull World Health Organ* **2020**;
417 98:558-68F.
- 418 16. Cheng Q, Gatton ML, Barnwell J, et al. Plasmodium falciparum parasites lacking histidine-rich protein
419 2 and 3: a review and recommendations for accurate reporting. *Malar J* **2014**; 13:283.
- 420 17. World Health Organization. Response plan to pfhrp2 gene deletions. Geneva, Switzerland, **2019**.
- 421 18. Bakari C, Jones S, Subramaniam G, et al. Community-based surveys for Plasmodium falciparum
422 pfhrp2 and pfhrp3 gene deletions in selected regions of mainland Tanzania. *Malar J* **2020**; 19:391.
- 423 19. Kaaya RD, Kavishe RA, Tenu FF, et al. Deletions of the Plasmodium falciparum histidine-rich protein
424 2/3 genes are common in field isolates from north-eastern Tanzania. *Sci Rep* **2022**; 12:5802.
- 425 20. Lyimo BM, Popkin-Hall ZR, Giesbrecht DJ, et al. Potential Opportunities and Challenges of Deploying
426 Next Generation Sequencing and CRISPR-Cas Systems to Support Diagnostics and Surveillance Towards
427 Malaria Control and Elimination in Africa. *Front Cell Infect Microbiol* **2022**; 12:757844.
- 428 21. World Health Organization. Master protocol for surveillance of pfhrp2/3 deletions and biobanking to
429 support future research. Geneva, Switzerland, **2020**.
- 430 22. Rogier E, McCaffery JN, Nace D, et al. Plasmodium falciparum pfhrp2 and pfhrp3 Gene Deletions
431 from Persons with Symptomatic Malaria Infection in Ethiopia, Kenya, Madagascar, and Rwanda. *Emerg*
432 *Infect Dis* **2022**; 28:608-16.
- 433 23. Teyssier NB, Chen A, Duarte EM, Sit R, Greenhouse B, Tessema SK. Optimization of whole-genome
434 sequencing of Plasmodium falciparum from low-density dried blood spot samples. *Malar J* **2021**; 20:116.
- 435 24. Jones S, Subramaniam G, Plucinski MM, et al. One-step PCR: A novel protocol for determination of
436 pfhrp2 deletion status in Plasmodium falciparum. *PLoS One* **2020**; 15:e0236369.
- 437 25. Rogier E, Bakari C, Mandara CI, et al. Performance of antigen detection for HRP2-based malaria rapid
438 diagnostic tests in community surveys: Tanzania, July-November 2017. *Malar J* **2022**; 21:361.
- 439 26. Thawer SG, Chacky F, Runge M, et al. Sub-national stratification of malaria risk in mainland Tanzania:
440 a simplified assembly of survey and routine data. *Malar J* **2020**; 19:177.

- 441 27. Plucinski MM, Herman C, Jones S, et al. Screening for Pfhrp2/3-Deleted Plasmodium falciparum,
442 Non-falciparum, and Low-Density Malaria Infections by a Multiplex Antigen Assay. *J Infect Dis* **2019**;
443 219:437-47.
- 444 28. Abuaku B, Amoah LE, Peprah NY, et al. Malaria parasitaemia and mRDT diagnostic performances
445 among symptomatic individuals in selected health care facilities across Ghana. *BMC Public Health* **2021**;
446 21:239.
- 447 29. Amoah LE, Abuaku B, Bukari AH, et al. Contribution of P. falciparum parasites with Pfhrp 2 gene
448 deletions to false negative PfHRP 2 based malaria RDT results in Ghana: A nationwide study of
449 symptomatic malaria patients. *PLoS One* **2020**; 15:e0238749.
- 450 30. Moser KA, Madebe RA, Aydemir O, et al. Describing the current status of Plasmodium falciparum
451 population structure and drug resistance within mainland Tanzania using molecular inversion probes.
452 *Mol Ecol* **2021**; 30:100-13.
- 453 31. Kong A, Wilson SA, Ah Y, Nace D, Rogier E, Aidoo M. HRP2 and HRP3 cross-reactivity and implications
454 for HRP2-based RDT use in regions with Plasmodium falciparum hrp2 gene deletions. *Malar J* **2021**;
455 20:207.
- 456 32. Kozycki CT, Umulisa N, Rulisa S, et al. False-negative malaria rapid diagnostic tests in Rwanda: impact
457 of Plasmodium falciparum isolates lacking hrp2 and declining malaria transmission. *Malar J* **2017**;
458 16:123.
- 459 33. Molina-de la Fuente I, Benito MJS, Flevaud L, et al. Plasmodium falciparum pfhrp2 and pfhrp3 Gene
460 Deletions in Malaria-Hyperendemic Region, South Sudan. *Emerg Infect Dis* **2023**; 29:154-9.

461

462 **Acknowledgements**

463 The authors acknowledge the contribution of the following project staff who participated in data
464 collection and/or laboratory processing of samples; Ruth B. Mbwambo, Ramadhani Moshi,
465 Dativa Pereus, Doris Mbata, Ezekiel Malecela, Muhidin Kassim, August Nyaki, Juma Tupa,
466 Idephonce Mathias, Godbless Msaki, Rashid Mtumba, Gasper Lugela, Francis Chambo, Neema
467 Barua, Salome Simba, Hatibu Athumani, Mwanaidi Mtui, Rehema Mtibusa and Tilaus Gustav.
468 The finance, administrative and logistic support team at NIMR: Christopher D. Masaka, Millen A.
469 Meena, Beatrice Mwampeta, Gracia L. Sanga, Neema Manumbu, Halfan Mwanga, Arison
470 Ekoni, Twalipo Mponzi, Pendael Nasary, Denis Byakuzana, Emmanuel Mnzava, Seth Nguhu,
471 Thomas Semdoe and Andrea Kimboi. Management of the National Institute for Medical
472 Research, National Malaria Control Program and Presidents Office-Regional Administration and
473 Local Government (Regional administrative secretaries of the 10 regions, and district officials
474 and staff from all 100 HFs. Technical and logistics support from the Bill and Melinda Gates
475 Foundation team; Philip Welkhoff, Jennifer Gardy, Estee Torok, Sevreina Smith, Janice

476 Culpepper, Lucy Hoffen, Maliha Anwar and Rosalyn Yearly. This study was funded by the Bill
477 and Melinda Gates Foundation (Inv. No. 002202).

478

479 **Disclaimer**

480 The findings and conclusions in this report are those of the author(s) and do not necessarily
481 represent the official position of the Centers for Disease Control and Prevention and the Bill and
482 Melinda Gates Foundation.

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502 **Tables**

503

504 **Table 1. Demographic and RDT characteristics of enrolled patients: Tanzania 2021.**

Region	Provided RDT and DBS (n, % of all)	Median age (years, IQR)	Female (n, %)	RDT positive (n, %)	RDT Discordant* (n, % of RDT positives)
Kagera	619 (7.9)	6 (2-17)	326 (52.7)	378 (61.1)	15 (4.0)
Dar es Salaam	591 (7.5)	21 (5-29)	303 (51.3)	373 (63.1)	4 (1.1)
Dodoma	694 (8.8)	13 (3-30)	368 (53.0)	379 (54.6)	8 (2.1)
Kiimanjaro	2,484 (31.6)	21 (6-39)	1,449 (58.3)	381 (15.3)	10 (2.6)
Tabora	532 (6.8)	3 (2-11)	287 (53.9)	379 (71.2)	7 (1.8)
Songwe	594 (7.6)	12 (3-26)	337 (56.7)	378 (63.6)	14 (3.7)
Njombe	605 (7.7)	17 (7-30)	348 (57.5)	381 (63)	10 (2.6)
Mtwara	598 (7.6)	5 (3-20)	348 (58.2)	389 (65.1)	3 (0.8)
Manyara	574 (7.3)	18 (6-29)	268 (46.7)	376 (65.5)	9 (2.4)
Mara	572 (7.3)	8 (3-21)	318 (55.6)	373 (65.2)	15 (4.0)
Total	7,863	15 (3-29)	4,352 (55.3)	3,787 (48.2)	95 (2.5)

* Positive Pf-pLDH band and negative HRP2 band

IQR: interquartile range; RDT: rapid diagnostic test; HRP2: histidine-rich protein 2; pLDH: pan-*Plasmodium* lactate dehydrogenase; DBS: dried blood spot

505

506

507

508

509

510

511

512

513

514


515

516

517

518 **Figures**

519



520

521


522 **Figure 1. Map of showing health facility enrollment sites in 10 regions which were**
523 **involved in the survey: Tanzania 2021. Individual health facilities are shown by red triangles.**

524

525

526


527



528

529 **Figure 2. Scatterplots of HRP2 (and HRP3, HRP2/3) antigen levels as compared with other**
530 ***Plasmodium* antigens.** Scatterplots represent data from all 7,847 DBS which were assayed by
531 bead-based multiplex assay for *Plasmodium* antigens. Antigen levels for HRP2/3 versus PfLDH
532 (A), pAldolase (B), and pLDH (C). Red shading indicates DBS with depressed or absent
533 HRP2/3 levels selected for subsequent *pfhrp2* and *pfhrp3* genotyping.

534



535

536 **Figure 3. Flow diagram for selection of specimens for genotyping of *pfhrp2* and *pfhrp3***

537 **with results: Tanzania, 2021.** Selection strategy included consideration of laboratory antigen

538 detection assay (on left), and RDT result at point-of-contact (on right). Terminal boxes display

539 *pfhrp2* and *pfhrp3* deletion genotypes for samples passing all quality steps.

540

541

542

543



544

545

546 **Figure 4. Locations of enrolment sites with identified *P. falciparum* infections with**
547 **deletions in *pfhrp2* or *pfhrp3*: Tanzania: 2021.** Regions that were sampled from are named
548 on the map, with an 'X' indicating location of sample identified with *pfhrp2* deletion (n=9) and
549 solid '•' indicating sample identified with *pfhrp3* deletion (n=6). A number in parentheses
550 indicates multiple deletions found at a single site.

551